U.S., May 6 -- ClinicalTrials.gov registry received information related to the study (NCT07566429) titled 'A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease' on April 28.
Brief Summary: The objective of this Phase 2, open-label, single group, one-time, fixed-dose study is to assess the safety and efficacy of bilateral intraputaminal infusion of AB-1005 (AAV2-GDNF gene therapy) in Japanese patients with moderate Parkinson's Disease (PD).
Study Start Date: July 27
Study Type: INTERVENTIONAL
Condition:
Parkinson Disease
Intervention:
DRUG: AB-1005
Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Bayer
Published by HT Digital Cont...